



Dr. Reddy's Laboratories Ltd.
8-2-337, Road No. 3, Banjara Hills,
Hyderabad - 500 034, Telangana,
India.

CIN : L85195TG1984PLC004507

Tel : +91 40 4900 2900

Fax : +91 40 4900 2999

Email :mail@drreddys.com

www.drreddys.com

April 19, 2024

National Stock Exchange of India Ltd. (Scrip Code: DRREDDY-EQ)

BSE Limited (Scrip Code: 500124)

Dear Sir/Madam,

Sub: Certificate under Regulation 40(9) of the Securities and Exchange Board of India (Listing Obligations and Disclosure Requirements) Regulations, 2015 for the year ended March 31, 2024.

We are enclosing herewith a copy of the yearly Compliance Certificate issued by the Company Secretary in Practice for the period from April 1, 2023 to March 31, 2024 under Regulation 40(9) of the Securities and Exchange Board of India (Listing Obligations and Disclosure Requirements) Regulations, 2015.

This is for your information and records.

Thanking you,

Yours faithfully,

For **Dr. Reddy's Laboratories Limited**

K Randhir Singh

Company Secretary, Compliance Officer & Head-CSR

CERTIFICATE UNDER REGULATIONS 40(9) OF SECURITIES AND EXCHANGE BOARD OF INDIA (LISTING OBLIGATIONS AND DISCLOSURE REQUIREMENTS) REGULATIONS, 2015 FOR THE YEAR ENDED 31st MARCH, 2024

We have examined all Registers, files and other documents relating to Dr. Reddy's Laboratories Limited (Company) having its registered office situated at 8-2-337, Road No.3, Banjara Hills, Hyderabad – 500034, Telangana, India maintained by the Registrar and Share Transfer Agent (RTA), M/s Bigshare Services Private Limited having its office at 306, 3rd Floor, Right Wing, Amrutha Ville, Opp. Yashoda Hospital, Raj Bhavan Road, Somajiguda, Hyderabad – 500082, Telangana, India pertaining to Equity Shares of the Company for the Financial Year from 1st April, 2023 to 31st March, 2024 for the purpose of issuing a Certificate as per Regulation 40(9) of Securities and Exchange Board of India (Listing Obligations and Disclosure Requirements) Regulations, 2015 and the Listing Agreement entered into by, Dr. Reddy's Laboratories Limited with National Stock Exchange of India Limited (NSE) and BSE Limited (BSE) and based on the information provided by the Company/RTA, we hereby certify that:

- A) the Company has delivered during the year ended on 31st March 2024 letter of confirmation(s) in respect of requests received during the period from 1st April, 2023 to 31st March, 2024 for duplicate and transfer/transmission requests within stipulated time.
- B) the Company has delivered during the year ended 31st March 2024, letter of confirmation(s) in respect of the requests received during the period from 1st April, 2023 to 31st March, 2024 for exchange of shares and name deletion within stipulated time;
- C) the Company has delivered during the year ended 31st March 2024, confirmation(s) in respect of the requests for split, replacement/renewal, subdivision, consolidation, replacement, or endorsement of calls/allotment monies, as applicable, during the financial year from 1st April, 2023 to 31st March, 2024.

Place : Hyderabad
Date : 19th April 2024

For R & A Associates

RASHIDA
HATIM
ADENWALA

(Rashida Hatim Adenwala)

Partner

FCS. No. 4020, C.P. 2224

UDIN: F004020F000187896

Digitally signed by RASHIDA HATIM ADENWALA
DN: cn=RASHIDA HATIM ADENWALA,
o=R & A Associates,
ou=4020, postalCode=500015,
st=Telangana,
serialNumber=1146, serialNumber.2=7723824632,
c=IN, cn=C3788044671674980319496, cn=RASHIDA HATIM
ADENWALA
Date: 2024.04.19 16:49:35 +05'30'